Arena Pharmaceuticals (ARNA +38%) resumes trading at $13.50 following the FDA's approval of its...

|About: Arena Pharmaceuticals, Inc. (ARNA)|By:, SA News Editor

Arena Pharmaceuticals (ARNA +38%) resumes trading at $13.50 following the FDA's approval of its weight-loss drug Belviq - formerly known as lorcaserin.